Biotech

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

2024-02-07 19:00 1204

* Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech  * Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reduc...

NouvNeu001 Achieves Milestone with Successful Dosing of First Patient, Signaling Smooth Progress in iRegene Therapeutics' Multicenter Clinical Trial for Innovative Novel Parkinson's Disease Therapy

2024-02-05 21:00 1369

WUHAN, China, Feb. 5, 2024 /PRNewswire/ -- iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation period...

Innovent Announces Retirement of CFO and Appointment of New CFO

2024-02-05 16:45 2265

ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other ...

Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery

2024-02-05 09:53 1426

HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery. The company has made remarkable technological breakthroughs in developing highly miniaturized and flexible robot...

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

2024-02-05 08:00 1187

* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. * Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stag...

Blossoming Flowers at the Top of the Biopharmaceutical Tree -- Reflections on the Flourishing of Sanyou's 4C Business

2024-02-03 08:00 2059

SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- In 1996, MDS Pharma Service invested in and established the first true Contract Research Organization (CRO) inChina, dedicated to clinical trial business for new drugs. This marked the official launch of the CRO industry inChina. The concept of CRO originat...

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

2024-02-02 22:00 1466

* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

2024-02-02 21:30 1897

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on Febru...

Fapon and Bio Farma Sign MOU for Medical Innovations

2024-02-02 16:30 1746

DONGGUAN, China, Feb. 2, 2024 /PRNewswire/ -- On February 1, 2024, Fapon, a global leading life science company, andBio Farma, a state-owned pharmaceutical holding company inIndonesia specializing in vaccines, life science products, and other pharmaceuticals, signed a memorandum of understanding ...

NABR Files Expanded Petition Challenging the Listing of Long-Tailed Macaques by the IUCN

2024-02-02 09:01 1534

WASHINGTON, Feb. 2, 2024 /PRNewswire/ -- Working with recognized, independent scientists, the National Association for Biomedical Research (NABR) filed an expanded petition today with the International Union for Conservation of Nature (IUCN) challenging the designation of the long-tailed macaque ...

NX Netherlands Receives IATA CEIV Pharma Certification for Its Warehouse Near Amsterdam Airport Schiphol

2024-02-01 14:00 1423

TOKYO, Feb. 1, 2024 /PRNewswire/ -- Nippon Express (Nederland) B.V. (hereinafter "NX Netherlands"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired CEIV Pharma certification (*), a quality certification for pharmaceutical transport established by the International Air Transport As...

Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development

2024-02-01 00:00 1259

TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is China Development Industrial Bank (CDIB), with s...

21ST.BIO OPENS A MORE SUSTAINABLE AVENUE FOR INDUSTRIAL SCALE DAIRY PROTEIN PRODUCTION

2024-01-31 16:47 907

* Global bioproduction leader 21st.BIO today announced it is now granting access to its precision fermentation technology platform to food and ingredient manufacturers, enabling sustainable production of dairy proteins at competitive cost.            * Access to 21st.BIO's technology represen...

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

2024-01-31 10:43 2488

SHANGHAI, Jan. 30, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platfor...

The Biotech Accelerator Unicorn Program: A Unique Collaboration between CKGSB and the UC San Diego Rady School of Management

2024-01-30 22:25 1582

SAN DIEGO, Jan. 30, 2024 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB) andUniversity of California San Diego (UC San Diego) Rady School of Management are proud to announce the launch of the Biotech Accelerator Unicorn Program, a pioneering joint program specifically designed to...

XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery

2024-01-30 21:00 1182

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking th...

Singleron launches the AccuraSCOPE® Single Cell Transcriptome

2024-01-30 18:05 1100

COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine,announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length...

MGI Unveils Comprehensive Expansion of Automation Product Lines for Life Science and Healthcare Research

2024-01-30 15:55 1579

The company will offer new and improved solutions for sample pre-treatment, sample preparation and integrated testing, leveraging its innovative technologies and expertise in genetic sequencing and multi-omics. SHENZHEN, China, Jan. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. (referred to as MGI...

Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation

2024-01-29 21:30 1238

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene. This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and genetic...

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

2024-01-29 21:08 1388

SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with...

12345678 ... 144

Week's Top Stories